Mahamaya Lifesciences Key Ratios
BSE: 544611
₹183.00
₹3.25
(1.81%)
As on 08-Sep-2026IST
Market cap
₹428 Cr
Revenue (TTM)
₹264 Cr
P/E Ratio
25.9
P/B Ratio
3.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 63.49 | 43.22 | -- |
| EBIT | -- | -- | 79.12 | 58.62 | -- |
| Net Profit | -- | -- | 148.02 | 68.13 | -- |
| EPS | -- | -- | 91.77 | 54.32 | -- |
| Book Value | -- | -- | 54.98 | 34.50 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| 7.09 | -- | 8.13 | 7.42 | 5.74 |
| Net Margin
| 3.59 | -- | 4.84 | 3.20 | 2.73 |
| Return on equity
| 26.65 | -- | 34.94 | 23.67 | 21.34 |
| Return on Capital
| 22.85 | -- | 26.23 | 21.52 | 20.81 |
| Return on Assets
| 6.58 | -- | 8.62 | 5.49 | 5.62 |
| Debt to Equity (x)
| -- | -- | 1.18 | 2.22 | 1.25 |
Profitability
ROCE
26.23
Higher than Peers by 14.00
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
26.23
|
21.52
|
20.81
|
16.12
|
--
|
|
Peer Median
|
12.22
|
21.63
|
27.13
|
26.41
|
--
|
ROE
34.94
Higher than Peers by 25.71
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
34.94
|
23.67
|
21.34
|
17.34
|
--
|
|
Peer Median
|
9.23
|
18.08
|
23.65
|
21.83
|
--
|
ROA
8.62
Higher than Peers by 2.63
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
8.62
|
5.49
|
5.62
|
4.90
|
--
|
|
Peer Median
|
5.98
|
9.92
|
11.99
|
10.73
|
--
|
EBIT Margin
8.13
Lower than Peers by 1.55
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
8.13
|
7.42
|
5.74
|
5.98
|
--
|
|
Peer Median
|
9.68
|
7.64
|
15.61
|
14.45
|
--
|
Net Margin
4.84
Lower than Peers by 0.79
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
4.84
|
3.20
|
2.73
|
3.02
|
--
|
|
Peer Median
|
5.63
|
8.97
|
12.29
|
11.31
|
--
|
Cash Profit Margin
5.57
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
5.57
|
4.15
|
3.66
|
4.10
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
63.49
Higher than Peers by 55.78
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
63.49
|
17.87
|
52.45
|
--
|
--
|
|
Peer Median
|
7.71
|
-11.85
|
28.76
|
12.22
|
--
|
EBIT Growth
79.12
Higher than Peers by 47.56
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
79.12
|
52.48
|
46.13
|
--
|
--
|
|
Peer Median
|
31.57
|
-36.92
|
24.92
|
27.46
|
--
|
Net Profit Growth
148.02
Higher than Peers by 117.43
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
148.02
|
39.14
|
37.72
|
--
|
--
|
|
Peer Median
|
30.59
|
-41.41
|
25.31
|
37.91
|
--
|
EPS Growth
91.77
Higher than Peers by 60.70
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
91.77
|
39.14
|
37.72
|
--
|
--
|
|
Peer Median
|
31.07
|
-42.07
|
26.92
|
38.53
|
--
|
Book Value Growth
100.43
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
100.43
|
26.85
|
23.77
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
1.18
Higher than Peers by 1.12
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
1.18
|
2.22
|
1.25
|
1.22
|
--
|
|
Peer Median
|
0.05
|
0.11
|
0.09
|
0.09
|
--
|
Short term debt to equity ratio
0.99
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
0.99
|
1.76
|
0.59
|
0.50
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.19
Lower than Peers by 0.88
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
1.19
|
1.12
|
1.13
|
1.11
|
--
|
|
Peer Median
|
2.07
|
1.63
|
1.80
|
1.85
|
--
|
Quick Ratio
0.44
Lower than Peers by 0.80
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
0.44
|
0.47
|
0.41
|
0.50
|
--
|
|
Peer Median
|
1.23
|
1.13
|
0.96
|
1.23
|
--
|
Interest Coverage
3.43
Lower than Peers by 8.79
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
3.43
|
2.16
|
2.65
|
2.96
|
--
|
|
Peer Median
|
12.22
|
12.03
|
32.38
|
25.98
|
--
|
Operating Efficiency
Debtors to sales
18.35
Lower than Peers by 12.19
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
18.35
|
17.52
|
6.95
|
10.13
|
--
|
|
Peer Median
|
30.54
|
25.72
|
30.34
|
28.66
|
--
|
Asset Turnover
1.76
Higher than Peers by 0.91
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
1.76
|
1.70
|
2.05
|
1.62
|
--
|
|
Peer Median
|
0.85
|
0.88
|
1.09
|
1.14
|
--
|
Receivable days
53.04
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
53.04
|
42.74
|
24.81
|
36.97
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
104.49
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
104.49
|
96.92
|
71.11
|
75.64
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
64.91
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
64.91
|
67.49
|
69.44
|
82.67
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
92.62
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
92.62
|
72.17
|
26.47
|
29.93
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
39.81
|
50.05
|
19.11
|
27.36
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.60
|
3.48
|
3.99
|
5.38
|
--
|
EV/EBITDA
2.74
Lower than Peers by 26.43
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
2.74
|
3.59
|
2.39
|
2.89
|
--
|
|
Peer Median
|
29.16
|
19.72
|
17.29
|
22.13
|
--
|
Market Cap
--
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4,155
|
3,052
|
3,521
|
3,428
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
